Elon Musk, the Trump campaign and ketamine: What to know about the powerful drug
New details about Elon Musk's relationship with ketamine have emerged a few days after the tech entrepreneur announced his departure from the White House.
Although Musk had previously mentioned using a "small amount once every other week," the billionaire X owner may have been using ketamine frequently enough on President Donald Trump's campaign trail for the drug to start causing some health issues, according to reporting from The New York Times.
Musk previously mentioned using the drug as a medical prescription to treat depression in an hour-long interview with former CNN host Don Lemon in March 2024, where he also denied abusing the drug.
Musk is not the only celebrity who has used ketamine. The late actor Matthew Perry was using ketamine under the care of a physician for the treatment of depression, although the levels of ketamine in his system at the time of his death in October 2023 weren't related to his last infusion. Other celebrities who have used the substance include Chrissy Teigen and Sharon Osborne.
Here's what to know about ketamine.
Need a break? Play the USA TODAY Daily Crossword Puzzle.
What is ketamine?
Ketamine is a dissociative anesthetic that has some hallucinogenic effects, according to the U.S. Drug Enforcement Administration.
It binds to the NDMA receptors and is essentially a 'stop' signal. It starts to interfere with the connection between your brain and your body.
The effects are dose-dependent, but it generally leads to a 'disconnected' feeling from you, your person – and your body. Symptoms range from unconsciousness (like when used in general anesthesia) to an 'out of body' experience or hallucinations.
Is ketamine legal?
Ketamine is a legal medication and is used as an injectable, short-acting anesthetic for use in humans and animals, the DEA says.
A ketamine derivative, esketamine under the brand name Spravato, is FDA-approved as a nasal spray to treat depression in adults, according to the National Institute on Drug Abuse. Ketamine has also been used off-label in dozens of clinics across the U.S. to treat other mental health conditions, such as anxiety, in combination with talk therapy.
However, most of the ketamine distributed in the U.S. is done so illegally, per the DEA. It's often diverted or stolen from legitimate sources, like veterinary clinics, or smuggled into the country.
Ketamine is classified as a Schedule III drug by the agency, which denotes substances "with a moderate to low potential for physical and psychological dependence."
In case you missed: Sharon Osbourne says ketamine helped her depression. Is this the next big trend?
Short- and long-term effects of ketamine
Short-term side effects of ketamine use may include headache, dizziness, sleepiness, feeling strange or 'loopy,' difficulty speaking, numbness, blurred vision or nausea, according to NIDA.
Long-term, heavy ketamine use is associated with memory problems, depression and anxiety. The drug may also cause gastrointestinal problems, abdominal pain popularly known as 'k-cramps' and uropathy, which is a blockage in the urinary tract that can lead to infections, or UTIs.
Contributing: Delaney Nothaft and Emily DeLetter, USA TODAY.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Subtle Differences Emerge Between FDA And CDC On COVID Vaccine Advice
An illustration picture shows vials with Covid-19 vaccine stickers attached and syringes with the ... More logo of the company Novavax. (Photo by JUSTIN TALLIS / AFP) (Photo by JUSTIN TALLIS/AFP via Getty Images) In a major policy shift last month, Food and Drug Administration officials proposed requiring new clinical trial research with respect to the effectiveness of COVID-19 vaccines in healthy people under 65, including pregnant women, before issuing an updated approval for a broader population. At the same time, in an update to its immunization schedule posted May 29th, the Centers for Disease Control and Prevention include the option of COVID-19 vaccines for healthy children and pregnant women. Based on the language used by CDC, it suggests the agency aims for a shared decision-making approach in which individuals consult with their doctor prior to getting a shot. We witnessed a preview of the new FDA approach when the agency made an unusual decision to limit the approval of the nation's only non-mRNA coronavirus vaccine, Novavax's nuvaxovid, for use only in adults 65 and older or those 12 to 64 who have at least one health problem that puts them at increased risk from COVID-19. To be indicated for a broader population, the FDA plans to require that vaccine makers conduct booster trials to demonstrate effectiveness in people under 65 or without certain risks. These trials could take a year to complete, according to a STAT report. As such, it's not something that can be accomplished prior to the autumn, even if Novavax, Pfizer, or Moderna, wished to pursue this pathway. Similar to annual flu shots, which adapt to new strains, COVID-19 boosters update immunity to target evolving variants. Data from several years of booster campaigns show lower hospitalization and death rates for boosted individuals compared to unvaccinated people or those who haven't gotten boosters. This particularly applies to the vulnerable subpopulations, stratified by age and underlying health conditions. The COVID-19 vaccines, both mRNA and non-mRNA, are recommended for anyone who is over 65 or who has a medical condition that can increase the risk of severe illness or death. Underlying conditions include, among other things, obesity, 'physical inactivity,' diabetes, clinical depression and being immunocompromised. It's estimated that between 100 and 200 million Americans will still be eligible for vaccination due to having such health issues. Nevertheless, this raises questions for people who don't have underlying health conditions and are under 65 but would like to get a COVID-19 shot this fall. The FDA and CDC appear to differ subtly in terms of their current advice for healthy individuals under 65. Is it possible for these folks to obtain a jab at the pharmacy with no questions asked? Or will they have to go to their doctor and be granted de facto permission to get the shot? Perhaps equally important, will their insurer pay for it? As the New York Times explains, insurance companies may serve as the 'gatekeepers by demanding medical documentation of an underlying condition before agreeing to cover the cost.' The out-of-pocket cost to patients could be as much $140 a shot. Top FDA officials Prasad and Makary advocate an 'evidence-based' approach to COVID-19 vaccination. They also write of aligning policy with Europe. Indeed, in most instances, European public health authorities have adopted a targeted approach that aims at ensuring the elderly and those with underlying health conditions get boosted. This means that outreach campaigns in European countries only target subpopulations for which the vaccine is recommended by the respective public health authority. This is unlike the universal recommendations previously issued by the CDC that didn't differentiate by age or risk factors. However, the European agencies in charge of vaccine approval, the EMA and MHRA, haven't suggested marketing authorization changes, such as narrowing the indication based on age, for any of the approved COVID-19 vaccines.
Yahoo
2 hours ago
- Yahoo
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding that could change the way such cancers are treated, cancer experts said on Sunday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in the risk of disease progression or death, said Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky believes the data will likely result in a new treatment paradigm. The trial involved 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as estrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40% of patients treated with aromatase inhibitors develop mutations in the estrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called Selective Estrogen Receptor Degraders (SERDS) block estrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to look for ESR1 mutations until 315 patients were identified. They were randomly assigned to either switch to camizestrant plus the CDK4/6 inhibitor (157 patients) or continue with standard treatment plus a placebo (158 patients). The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr. Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Separately, adding AstraZeneca's immunotherapy durvalumab to standard treatment before and after surgery in patients with early-stage stomach and esophageal cancers helped extend the time patients had without cancer progression or recurrence compared to chemotherapy alone. The global study of nearly 950 patients tested durvalumab, sold under the brand Imfinzi, in combination with a chemotherapy regimen called FLOT given around the time of initial cancer surgery. Patients in the durvalumab plus FLOT arm experienced a 29% better event-free survival than those who received the chemotherapy regimen. "We demonstrate that immunotherapy works in early-stage disease, which is great," lead study author Dr. Yelena Jarnigan of Memorial Sloan Kettering Cancer Center in New York told reporters at the meeting. "We did not see any new safety signals, so this will change practice for our patients, which is exciting to see." Both studies were published on Sunday in the New England Journal of Medicine.
Associated Press
4 hours ago
- Associated Press
DEA's War on Marijuana Science: How Bureaucratic Clowns Are Blocking Clinical Trials While Spreading Fear Based Fiction
Duane Boise MMJ CEO opined 'Now all eyes turn to DEA Administrator-nominee Terrance Cole. Thus far, his public marijuana statements have been evasive, his confirmation answers noncommittal, and his track record steeped in anti-cannabis fearmongering. However, as the DEA boss, he needs to stop the clown show in comparing cannabis to methamphetamine with no clinical basis and distributing memes claiming cannabis lowers sperm count by 50%, despite contradictory evidence'. WASHINGTON, DC / ACCESS Newswire / June 1, 2025 / The U.S. Drug Enforcement Administration (DEA) has once again embarrassed itself, this time by promoting the ludicrous claim that marijuana may cause more psychosis than methamphetamine. This sensationalist garbage-circulated through their 'Just Think Twice' campaign-was framed with all the seriousness of a peer-reviewed journal, yet backed by none of the clinical evidence. Let's be clear: this is not science. This is propaganda. And it's especially dangerous coming from the very agency actively obstructing legitimate, federally regulated research into the medical use of cannabis. At the center of the absurdity is a cherry-picked quote from Oregon psychiatrist David Rettew, claiming that marijuana 'raises the risk of psychotic disorders more than other drugs, even methamphetamines.' There's no clinical study cited, no peer-reviewed data, no rigorous comparative analysis just an offhand opinion that the DEA spun into a headline to keep cannabis in the shadows. Meanwhile, MMJ BioPharma Cultivation-one of the only companies in the country following federal law to the letter-is still barred from growing cannabis for FDA-authorized clinical trials. Let that sink in. The DEA refuses to let a federally compliant company conduct gold-standard scientific research, while simultaneously pushing psychobabble memes about marijuana and infertility, emojis that 'mean drugs,' and 'natural highs' like pet stores and Instagram followers. This is not a public health agency-it's a clown car with a badge. MMJ BioPharma: The Victim of Bureaucratic Sabotage MMJ BioPharma Cultivation has: And yet, the DEA has refused for seven years to issue a Schedule I bulk manufacturing registration. Why? Not because of safety concerns. Not because of noncompliance. But because-unlike Curaleaf, Cookies, and other recreational giants-MMJ isn't playing the political lobbying game or hiding behind state loopholes. MMJ is doing it the right way, and that seems to be precisely the problem. While cartels and corporate exporters freely move THC products overseas through 'strategic partnerships' and shadowy legal gymnastics, MMJ is being crushed under the weight of federal inaction. The DEA has even subjected them to a constitutionally defective administrative hearing-overseen by an ALJ whose very authority the DOJ has now disavowed. DEA: Champion of Pseudoscience and Policy Hypocrisy Let's talk about the DEA's latest intellectual triumphs: Meanwhile, the DEA continues to ignore the 2023 HHS recommendation to reschedule cannabis, based on real, peer-reviewed, FDA-analyzed scientific data. You cannot claim to care about psychosis while blocking the very clinical trials designed to test safety, efficacy, and neurological effects. That's not science. That's obstruction. Terrance Cole's Choice: Lead or Rubber Stamp the Marijuana Rot Now all eyes turn to DEA Administrator-nominee Terrance Cole. Thus far, his public statements have been evasive, his confirmation answers noncommittal, and his track record steeped in anti-cannabis fearmongering. If Cole refuses to address the unconstitutional DEA tribunals, if he refuses to approve MMJ's license after seven years of federal compliance, if he continues parroting outdated 'gateway drug' nonsense-then the agency's credibility, already on life support, will collapse entirely. End the Madness. Let Science Lead. The DEA's current posture is untenable. It is promoting misinformation, blocking research, and enabling a regulatory regime that favors corporate exports and illicit markets while punishing pharmaceutical innovators. MMJ BioPharma has done everything right. The DEA has done everything wrong. It's time to stop the clown show, shut down the pseudoscience, and issue the damn license. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
